Predictive Oncology (NASDAQ: POAI), through its subsidiary
Helomics, is sequencing ovarian cancers as part of a CancerQuest 2020 project,
building the largest ovarian multi-omic database in the world. An article
discussing the company reads, “As part of its CancerQuest 2020 project,
Predictive Oncology, through Helomics, recently signed a collaborative
agreement with UPMC-Magee to establish a data- and
artificial-intelligence-driven approach to treating ovarian cancer. Based on
the agreement, the partnership is designed to validate the significant value of
using AI-powered decision-making for identifying specific treatments on
specific genotypes to predict clinical outcomes for ovarian cancer patients. .
. . Helomics has also begun sequencing retrospective ovarian cancer cases from
the UPMC-Magee collaboration (http://ibn.fm/I4Lnb).
As part of the sequencing process, Helomics is analyzing the mutations in the
tumor (genome) and the expression of genes (transcriptome) in order to build a
comprehensive multi-omic picture of the tumor. That information can then be
brought together with Helomics’ data set of drug-response profiles to build an
AI-driven predictive model of ovarian cancer.”
To view the full article, visit http://ibn.fm/9i0uR
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (domestic, international, clinical, CRO and DCHIP), which contain four
subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient-treatment decisions by providing an
evidence-based road map for therapy. In addition to its proprietary, precision
oncology platform, Helomics offers boutique CRO services that leverage its
TruTumor(TM), patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered,
proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified, they can be used in
TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the
development of patient-specific treatment options. Helomics and TumorGenesis
are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division
markets its patented and FDA-cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through both domestic
and international divisions. The company has achieved sales in five of the
seven continents through both direct sales and distributor partners. For more
information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment